Tag: cause

Confronting the Unthinkable and Pushing Beyond Industry StandardsOMAHA, Neb., June 10, 2026 /PRNewswire/ -- During a time when aviation safety is drawing increased attention...

FDA clearance enables initiation of first-in-human Phase 1/2a clinical trial evaluating LM-LLO-TT, Matter Bio's attenuated Listeria monocytogenes-based immunotherapy candidate.SAN FRANCISCO, June 10, 2026 /PRNewswire/ --...

Customers Can Now Order Fuel and 5,000+ Everyday Essentials in a Single App; Rollout to Additional Cities Planned

Customers Can Now Order Fuel and 5,000+ Everyday Essentials in a Single App; Rollout to Additional Cities Planned

GREATER SUDBURY, ON, June 10, 2026 /CNW/ - Frontier Lithium Inc. ("Frontier") announces that it has entered into a non-binding memorandum of understanding (the...

JERICHO, N.Y., June 10, 2026 (GLOBE NEWSWIRE) -- Kimco Realty® (NYSE: KIM) today announced that its operating subsidiary, Kimco Realty OP, LLC (“Kimco OP”), intends to offer, subject to market and other conditions, $500,000,000 aggregate principal amount of exchangeable senior notes due 2031 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Kimco Realty Corporation (“Kimco”) will fully and unconditionally guarantee the notes on a senior, unsecured basis. Kimco OP also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $75,000,000 aggregate principal amount of notes.

Continues to advance the project and is working directly with the hyperscaler customer

Continues to advance the project and is working directly with the hyperscaler customer

Trading to begin at market open on Monday, June 15, 2026TORONTO, June 10, 2026 /CNW/ - Hemlo Mining Corp. (TSXV: HMMC) (OTCQX: HMMCF) (the...

Technology / E-Motion™ Platform IntelligenceVision Marine is extending a key display supply and integration relationship through 2029, supporting the connected digital interface of its...

New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany

New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering-related expenses, are expected to be approximately $600 million. All of the shares and pre-funded warrants in the Offering are to be sold by Tango. The Offering is expected to close on or about June 11, 2026, subject to customary closing conditions. In addition, Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.

Minami Maeda appointed as CEO to drive faster, more focused execution toward U.S. commercial launchMickey Mikitani will continue to provide strategic direction and remains...